Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Trial Profile

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 28 Feb 2022 Status changed from active, no longer recruiting to completed.
    • 13 May 2021 According to a Sellas Life Sciences Group media release, the data safety monitoring board recommended that, given the small size of the study and in order to preserve the statistical power of the study, the primary analysis of the study be completed upon the completion of three years of follow-up on every patient or until more events are collected. The company expects the primary analysis in this study to be completed by the end of 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top